Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas Fichert is active.

Publication


Featured researches published by Thomas Fichert.


Biomedical Chromatography | 2009

Development and validation of an HPLC method to quantify 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids.

Matthias Frischmann; Johanna Spitzer; Michael Fünfrocken; Stefan Mittelmaier; Melanie Deckert; Thomas Fichert; Monika Pischetsrieder

A method was developed and validated to quantify 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids by high-performance liquid chromatography with UV detection after derivatization with o-phenylenediamine. The advantages of this method compared with direct HPLC analysis are (i) the possibility of quantifying 3,4-dideoxyglucosone-3-ene simultaneously together with other glucose degradation products, (ii) the compatibility of the method with MS detection for unequivocal identification of the analyte and (iii) a bathochromic shift of the UV absorbance maximum which leads to higher selectivity. The validated method was used to measure 3,4-dideoxyglucosone-3-ene concentrations additionally to the glucose degradation products 3-deoxyglucosone, methylglyoxal, glyoxal, 5-hydroxymethylfurfural, 2-furaldehyde, formaldehyde and acetaldehyde in 19 commercial products for peritoneal dialysis.


Journal of Chromatography B | 2010

Identification and quantification of the glucose degradation product glucosone in peritoneal dialysis fluids by HPLC/DAD/MSMS.

Stefan Mittelmaier; Michael Fünfrocken; Dominik Fenn; Thomas Fichert; Monika Pischetsrieder

Glucose degradation products (GDPs) formed during heat sterilization of peritoneal dialysis (PD) fluids exert cytotoxic effects and promote the formation of advanced glycation end-products in the peritoneal cavity. As a result, long-term application of continuous ambulatory peritoneal dialysis is limited. The composition and concentration of GDPs in PD fluids must be known to evaluate their biological effects. The present study describes a targeted screening for novel GDPs in PD fluids. For this purpose, dicarbonyl compounds were converted with o-phenylenediamine to give the respective quinoxaline derivatives, which were selectively monitored by HPLC/diode array detector. Glucosone was thereby identified as a novel major GDP in PD fluids. Product identity was confirmed by LC/MSMS analysis using independently synthesized glucosone as a reference compound. Furthermore, a method was developed to quantify glucosone in PD fluids by HPLC/UV after derivatization with o-phenylenediamine. The methods limit of detection was 0.6 microM and the limit of quantitation 1.1 microM. A linear calibration curve was obtained between 1.1 and 113.9 microM (R(2)=0.9999). Analyzed at three different concentration levels, recovery varied between 95.6% and 102.0%. The coefficient of variation ranged between 0.4% and 4.7%. The method was then applied to the measurement of glucosone in typical PD fluids. Glucosone levels in double chamber bag PD fluids varied between not detectable and 6.7 microM. In single chamber bag fluids, glucosone levels ranged between 28.7 and 40.7 microM.


Archive | 2010

Multi-chamber bag

Matthias Brandl; Philippe Laffay; Michael Herrenbauer; Thomas Fichert; Franz Kugelmann; Jörn Hörmann


Archive | 2011

Molecularly imprinted polymers for eliminating metabolites

Thomas Fichert; Ingo Bichlmaier


Archive | 2011

Pharmazeutische Zusammensetzungen enthaltend substituiertes 6-Deoxy-6-sulfanylcyclodextrin

Ingo Bichlmaier; Thomas Fichert; Johannes Gerber


Archive | 2011

PHARMACEUTICAL COMPOSITION CONTAINING CYCLODEXTRIN COPOLYMER

Thomas Fichert; Ingo Bichlmaier


Archive | 2011

Concentrate for medical solutions, production thereof and use thereof in dialysis

Thomas Schweitzer; Thomas Fichert; Pascal Mathis


Archive | 2011

Pharmaceutical compositions containing substituted 6-deoxy-6-sulfanylcyclodextrin

Thomas Fichert; Johannes Gerber; Ingo Bichlmaier


Archive | 2011

Esterified Polysaccharide Osmotics

Dominik Fenn; Thomas Fichert; Thomas Schweitzer; Ingo Bichlmaier


Archive | 2011

Vorrichtung für die peritonealdialyse

Thomas Fichert; Ingo Bichlmaier

Collaboration


Dive into the Thomas Fichert's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge